This is a working overview of 瑞他鲁肽, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
=== Protein composition === EPCIP in humans has higher cysteine and lower valine concentrations than expected compared to other human proteins. This trend, as showed in Table 1, is the same for other mammals. It does not, however, occur in taxa other than mammalia.
=== Intein-containing proteins === An intein is a protein contained within another protein, the extein. Parasitic DNA infects an intein gene, which encodes an endonuclease. The resulting cDNA (complementary DNA) encodes the extein along with the intein. The intein contains a self-cleaving domain, which has the endonuclease nested within it. The intein domain performs two proteolytic cleavages at its own N-terminus and C-terminus and releases from the extein, separating it in two fragments. This two fragments are then spliced together and the extein remains as a completely functional protein. The N-terminal residue of the intein domain must be a serine, threonine or cysteine, and it attacks its preceding peptide bond in order to form an ester or a thioester. The first residue of the second portion of the extein must be a serine, threonine or cysteine as well, and this second nucleophile forms a branched intermediary. The C-terminal residue of the intein domain is always an asparagine, which cyclizes to form a succinimide, cleaving its own peptide bond and releasing the intein from the extein. Finally, in the extein the ester or thioester bond is rearranged to form a normal peptide bond. There are three known families of intein-containing proteins (N9, N10 and N11) all of them included in the PD clan, which contains proteolytic enzymes of different catalytic types. The tertiary structure has been solved for the intein V type proton ATPase catalytic subunit (Saccharomyces cerevisiae), a member of family N9 and for several inteins from family N10.
Nando's opened its first restaurants within the United Kingdom, in 1992, in the west London suburbs of Ealing and Earls Court, initially focusing on takeaway food. The UK arm, owned by the Enthoven family via a private equity company, struggled until chairman Dick Enthoven put his son Robert in control. The focus then moved from takeaways to a mixed-service (counter ordering and table service) model. This decision was taken after Nando's partnered with Harrison, a branding and design agency. They also advised Nando's to design each restaurant individually so no two restaurants were the same, a brand characteristic of the chain. In 2013, the company employed around 8,000 staff in the UK and had over 280 branches, with about 60 serving food conforming with Islamic dietary laws. In 2010, Nando's UK won the Sunday Times's 'best place to work' award in the big company category. Its sauces and marinades were also retailed in UK supermarkets. Nando's claims to have the largest collection of South African art in the UK, with over 5,000 works displayed in restaurants; original artworks are commissioned by the company. In March 2020, all of Nando's UK restaurants closed temporarily due to nationwide lockdown rules introduced by the government to limit the spread of COVID-19. In late April 2020, Nando's reopened select locations for delivery and collection services, with many more locations opening throughout May. In early July 2020, the restaurant chain started reopening a few of its outlets for eat-in service.
Independent Order of Sons of Abraham - Founded in 1892 by a group of Jewish men who were already members of the Masons, Sons of Benjamin, and the Order of B'rith Abraham. Membership in 1899 almost exclusively in New York and Brooklyn, numbered about 2,400 divided equally between men and women. Independent Order of Sons of Benjamin - Founded in 1877 in New York by a group of men who were already members of the Brith Abraham. By 1899 it had spread to the "principal cities of the United States and the Dominion of Canada." It authorized the creation of female lodges, of which there were about 20 in 1899. In 1899 there were about 18,000 male members and 2,500 women. In 1918 it had 800 members in 25 lodges, of which 450 were located in New York City with 18 lodges. Its headquarters in 1918 were at 953 Third Avenue. Offered the "usual secret society forms, and privileges". The emblem was a triangle between the letters F and P with an L under it. Offered insurance against death under the Metropolitan Life Insurance Company. Independent Western Star Order - Founded in 1894. The Eastern Division was headquartered at 40 Rivington Street. Had 21,000 members in 1918, with 2000 members in 24 lodges in New York City. Offered accident, death, and burial insurance May or may not be related to an order of the same name operating out of Chicago. Independent Workmens Circle - Founded in 1906 in Boston. Open to working men and women and "those in sympathy with the cause of labor". In 1923 had 77 lodges with 5,726 benefit members. Headquarters 86 Leverett Street, Boston.
Sources: en.wikipedia.org
In RNA synthesis, the 2'-hydroxy group is protected with TBDMS (t-butyldimethylsilyl) group. or with TOM (tri-iso-propylsilyloxymethyl) group, both being removable by treatment with fluoride ion. The phosphite moiety also bears a diisopropylamino (iPr2N) group reactive under acidic conditions. Upon activation, the diisopropylamino group leaves to be substituted by the 5'-hydroxy group of the support-bound oligonucleotide (see "Step 2: Coupling" below).
=== Conservative === There is currently no medical recommendation about how to manage an inguinal hernia condition in adults, due to the fact that, until the early 2010s, elective surgery used to be recommended. The hernia truss (or hernia belt) is intended to contain a reducible inguinal hernia within the abdomen. It is not considered to provide a cure, and if the pads are hard and intrude into the hernia aperture, they may cause scarring and enlargement of the aperture. In addition, most trusses with older designs are unable to effectively contain the hernia at all times, because their pads do not remain permanently in contact with the hernia. The more modern variety of truss is made with non-intrusive flat pads and comes with a guarantee to hold the hernia securely during all activities. They have been described by users as providing greater confidence and comfort when carrying out physically demanding tasks. However, their use is controversial, as data to determine whether they help prevent hernia complications is lacking. A truss also increases the probability of complications, which include strangulation of the hernia, atrophy of the spermatic cord, and atrophy of the fascial margins. This allows the defect to enlarge and makes subsequent repair more difficult. Their popularity is nonetheless likely to increase, as many individuals with small, painless hernias are now delaying hernia surgery due to the risk of post-herniorrhaphy pain syndrome. Elasticated pants used by athletes may also provide useful support for the smaller hernia.
Due to limited data however, more research on potential tolerance and withdrawal effects of moderate doses of doxepin is needed. At these doses of doxepin, dry mouth, an anticholinergic effect, was common (71%), and other side effects such as headache (25%), increased appetite (21%), and dizziness (21%) were also frequently observed, although these adverse effects were notably not significantly more frequent than with placebo in the study in question. In any case, taken together, higher doses of doxepin than very low doses are associated with an increased rate of side effects as well as apparent loss of hypnotic effectiveness with chronic treatment. Doxepin at a dose of 25 mg/day for 3 weeks has been found to decrease cortisol levels by 16% in adults with chronic insomnia and to increase melatonin production by 26% in healthy volunteers. In individuals with neuroendocrine dysregulation in the form of nocturnal melatonin deficiency presumably due to chronic insomnia, very-low-dose doxepin was found to restore melatonin levels to near-normal values after 3 weeks of treatment. These findings suggest that normalization of the hypothalamic–pituitary–adrenal axis and the circadian sleep–wake cycle may be involved in the beneficial effects of doxepin on sleep and insomnia.
Biden entered office nine months into a recovery from the COVID-19 recession and his first year in office was characterized by robust growth in real GDP, employment, wages, and stock market returns, amid significantly elevated inflation. Real GDP grew 5.9%, the fastest rate in 37 years. Amid record job creation, the unemployment rate fell at the fastest pace on record. By the end of 2021, inflation rates measured by the consumer price index (CPI) reached a nearly 40-year high of 7.1%, which was partially offset by the highest nominal wage and salary growth in at least 20 years. The inflation rate peaked at 9% in June 2022. The inflation rate reached 2.9% and core inflation rate reached 3.2% on an annual basis in December 2024, the last full month of Biden's term. Between December 2020 and December 2024, CPI rose 21.3% overall, with an annualized inflation rate of 5.3% throughout Biden's term in office. The inflation rate remained above the Federal Reserve's 2% target every month since March 2021, resulting in elevated interest rates to combat inflation. Average wages increased 19% throughout Biden's presidency, falling behind inflation. The unemployment rate declined by over 2% and real GDP grew 11% during Biden's term. Total household net worth increased by 28%, largely driven by stocks and real estate. The national debt grew to $36.2 trillion, with a debt to GDP ratio of 123% and a deficit to GDP ratio of 6% in FY 2024. In February 2023, the unemployment rate fell to 3.4%, a 53-year low.
== Athletic tracking and self-tracking uses == Hemoglobin can be tracked noninvasively, to build an individual data set tracking the hemoconcentration and hemodilution effects of daily activities for better understanding of sports performance and training. Athletes are often concerned about endurance and intensity of exercise. The sensor uses light-emitting diodes that emit red and infrared light through the tissue to a light detector, which then sends a signal to a processor to calculate the absorption of light by the hemoglobin protein. This sensor is similar to a pulse oximeter, which consists of a small sensing device that clips to the finger.
Sources: en.wikipedia.org
According to the architect, "The lobby mimics the typical Five Guys restaurant with red and white tile, tall tables, Freestyle Coke machine and signature peanut boxes." In 2023, they moved their headquarters to a new location in Alexandria, Virginia. In 2020, the first Five Guys location with a drive-through window opened in Surfside Beach, South Carolina. The franchisee retained it from the former business in the building in light of COVID-19 pandemic safe practices.
Cereblon is a protein that in humans is encoded by the CRBN gene. The gene that encodes the cereblon protein is found on the human chromosome 3, on the short arm at position p26.3 from base pair 3,190,676 to base pair 3,221,394. CRBN orthologs are highly conserved from plants to humans.
=== Occurrence in space === Nitriles are among the most abundant organic molecules in space, and more than ten distinct compounds have been unequivocally detected. Hydrogen cyanide was one of the first polyatomic species identified in space and occurs there relatively frequently and in substantial quantities. Other nitriles detected in space include acetonitrile and aminoacetonitrile, as well as butyronitrile, cyanoacetylene, and cyanopolyins containing two to five conjugated triple bonds. Hydrogen cyanide, cyanoacetylene, and cyanogen are present in the atmosphere of Saturn's moon Titan.
=== PMB === PMB (Probability Matrix from Blocks) of 2004 uses the additivity of evolutionary distances to improve on BLOSUM's analysis of the BLOCKS database. The up-to-date 2001 version of BLOCKS was used to generate a new set of BLOSUM matrices. The "observed substitution frequencies" found in these BLOSUM matrices are used to estimate actual substitution frequencies (with higher evolutionary distance, i.e. lower r, some later replacement can mask earlier replacements). PMB thus defines a true evolutionary model like PAM and JTT do. It is not a symmetric matrix.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.